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ENDOTHELIAL ADHERENS AND TIGHT JUNCTIONS IN VASCULAR 
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Endothelial cells lining the vessel wall are connected by adherens, tight and gap 
junctions. These junctional complexes are related to those found at epithelial junctions but 
with notable changes in terms of specific molecules and organization. Endothelial junctional 
proteins play important roles in tissue integrity but also in vascular permeability, leukocyte 
extravasation and angiogenesis. In this review, we will focus on specific mechanisms of 




The endothelium is located at the inner side of all vessel types and is constituted by a 
monolayer of endothelial cells. Interendothelial junctions contain complex junctional 
structures, namely adherens junctions (AJ), tight junctions (TJ) and gap junctions (GJ), 
playing pivotal roles in tissue integrity, barrier function and cell-cell communication, 
respectively. The endothelium constitutes the vascular barrier with regulated permeability 
properties between the blood and the underlying tissues. Quiescent endothelium may be 
subjected to stimuli inducing leukocyte extravasation at inflammatory sites and sprouting 
angiogenesis. Both processes have a strong impact on endothelial cell-cell junctions. In this 
review, we will focus on endothelial AJ and TJ as well as interendothelial-specific molecules 
or mechanisms in resting and activated vessels. 
 
Histology of endothelial junctions 
The junctional structures located at the endothelial intercellular cleft are related to those 
found in epithelia; however, their organization is more variable and in most vascular beds 
their topology is less restricted than in epithelial cells. AJ, TJ and GJ are often intermingled 
and form a complex zonular system with variations in depth and thickness of the 
submembrane plaque associated with the junctional structure [1, 2]. As opposed to epithelial 
cells, GJs are often observed close to the luminal surface. Therefore, the term “apical 
junction” used to collectively designate epithelial TJ and AJ may not be applied to the 
endothelium. 
Another distinction comes from the difference in cell thickness. With some exceptions, 
cell body thickness of microvascular endothelium is less than 0.3 m [2]. Overlapping strands 
of adjacent endothelial cells form contact domains of 0.5-0.9 m. However, endothelial cell-
cell contacts of some other vessels, including arteries and high endothelial venules, may reach 
3-10 m (Fig. 1) (deduced from [1, 2]). Outside of the electron-dense junctional structures, 
the intercellular cleft is lined by parallel plasma membranes of neighbor cells separated by 10-
20 nm.  
Finally, endothelial intercellular domains differ from those of epithelial cells by the 
absence of desmosomes [2]. The intermediate filaments, constituted in the endothelium by 
vimentin molecules, are poorly linked to cell-cell contacts. However, as opposed to the 
situation in epithelia, the vimentin filaments may be linked to endothelial AJ in junctional 
structures similar to desmosomes, called complexus adherens [3-8]. These structures 
originally described in lymphatic endothelium may have a broader distribution in the vascular 
tree. 
It must be stressed that interendothelial junctions are dynamic structures, subjected to 
multiple regulations. Furthermore, leukocytes extravasate at inflammatory sites (mostly in 
postcapillary venules) either through transcellular or paracellular routes. Extravasation 
through the intercellular junction is a rapid and regulated process, during which the leukocyte 
is squeezed in the cleft (diapedesis), followed by rapid junction reformation. 
 
Adhesive proteins located at endothelial cell-cell contacts 
A number of proteins exhibiting homophilic adhesive activities are located at 
interendothelial contacts (Fig. 2). Some of them are specific to endothelial cells (e.g., VE-
cadherin [9, 10], claudin-5 [11]) while others are common with epithelial cells (e.g., occludin 
[12], junctional adhesion molecule (JAM)-A [13], nectins [14, 15], claudins (see references 
below) and connexins [16]), blood cells (e.g., PECAM/CD31 [17], endothelial cell-selective 
adhesion molecule (ESAM) [18, 19], JAM-A, -C, CD99 (reviewed in [20]), smooth muscle 
cells (S-endo-1/CD146 [21]) or mesangial/trophoblast cells (protocadherin (Pcdh)12/VE-
cadherin-2 [22]). These proteins may be part of organized junctional structures, such as VE-
4 
cadherin in AJ, claudins and occludin in TJ, or connexins in GJ, while others are independent, 
such as PECAM, CD99, S-endo-1 or Pcdh12. The JAMs are associated with TJ through 
intracellular components without being directly involved in TJ strand formation.  
Interendothelial adhesive proteins are implicated at different levels in endothelial cell-cell 
interaction and tissue integrity. Some of them have a dual function as they also participate in 
leukocyte extravasation via homophilic (PECAM, CD99, JAM-A, -C) or heterophilic (JAM-
A, -B, -C) interactions (reviewed in [20]).  
 
THE ENDOTHELIAL ADHERENS JUNCTION 
 
The VE-cadherin-based complex and its physiological role 
VE-cadherin is the transmembrane component of endothelial AJ [23]. It is a type II 
cadherin harboring high adhesive activity [24]. Several biochemical evidences showed that 
VE-cadherin extracellular domains form hexamers in solution [25, 26]. Electron microscopy 
data support this view and allowed to propose a model in which VE-cadherin dimers interact 
in trans through their extracellular domain 1 and VE-cadherin trimers interact in cis via their 
extracellular domain 4 (Fig. 3) [27].  
VE-cadherin intracellular domain is similar to other classical cadherins. It contains a 
proximal binding site for p120 and p0071, and a distal binding site for ß-catenin and 
plakoglobin (Fig. 4, left). Both ß-catenin and plakoglobin are linked to -catenin, which may 
further interact with -actinin and vinculin (see [28] and references therein). The identity of 
the molecular link for the actin filament anchorage to the cadherin-catenin complex is still a 
question of debate [29]. As previously indicated, the VE-cadherin complex may associate 
with the vimentin cytoskeleton in some vascular locations [3-8]. This association is mediated 
by either plakoglobin or p0071, both interacting with desmoplakin, which in turn associates 
with vimentin (Fig. 4, right). The VE-cadherin complex also transiently or permanently 
associates with signaling partners (see below), and with a specific apical-basal polarity 
complex, through direct interaction with PAR-3 and PAR-6 [30].  
The precise mechanisms of VE-cadherin-based junction formation remain mostly 
unexplored. However, Delanoë-Ayari et al. [31] proposed a model in which VE-cadherin 
lateral clustering may be achieved by membrane tension and free VE-cadherin molecule 
diffusion rather than a cytoskeleton-driven mechanism. Consistent with this hypothesis, VE-
cadherin clusters forming artificial AJ were observed by assembly of VE-cadherin 
extracellular domains at the surface of liposomes [32]. As described below, the first cell-cell 
contacts may be achieved by nectin interaction, which may facilitate cadherin binding. 
VE-cadherin was shown to be specifically located at junctions of all endothelium 
subtypes [9]. VE-cadherin mRNA were observed at the onset of vasculogenesis in the mouse 
embryo [10]. Its extraendothelial expression has been observed in case of vascular mimicry 
(the extravillous cytotrophoblasts replacing the spiral artery endothelium [33] or melanoma 
cells lining tumor vessels [34]), in circulating endothelial progenitors [35] and in podocytes 
[36].  
The VE-cadherin gene yields a single transcript and its promoter contains functional sites 
for transcription factors such as Ets and Sp1 family members, as well as Tal [37-40]. 
Although constitutively expressed by endothelial cells, VE-cadherin expression is enhanced 
by basic FGF in angiogenic situations [41]. Furthermore, Tal, a bHLH transcription factor 
dramatically upregulated during angiogenesis, activates VE-cadherin transcription [40].  
VE-cadherin adhesive properties are essential for optimal homotypic cell interaction; 
however, the observation that VE-cadherin-deficient embryos retained electron-dense 
endothelial junctions indicates that some redundancy exist between the several homophilic 
adhesive proteins located at the endothelial surface [42]. Furthermore, VE-cadherin-deficient 
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embryos exhibited defective capacities in sprouting angiogenesis resulting in embryonic death 
at midgestation, suggesting that VE-cadherin has signaling properties required for vascular 
morphogenesis. The dramatic phenotype of VE-cadherin-deficient embryos was similar to 
that obtained with partial truncation of VE-cadherin cytoplasmic domain [43]. This feature 
further points to the implication of VE-cadherin in intracellular signaling.  
The contribution of VE-cadherin in neovessel formation has been further demonstrated in 
adults by experiments using antibodies directed against specific VE-cadherin epitopes, 
unmasked during angiogenesis, that abrogated angiogenesis and tumor growth in mice [44-
46].  
Other cadherins, namely N-cadherin [47], T-cadherin [48] and Pcdh12 [22, 49], have also 
been located in endothelial cells. Albeit abundant in endothelium, N-cadherin is not or poorly 
located at interendothelial junction [47]. Several converging studies indicate that this 
molecule promotes heterotypic interactions with perivascular cells such as pericytes [50, 51]. 
T-cadherin has been identified in endothelium of human aorta [48]. In vitro studies indicate 
that T-cadherin may participate to various cellular processes, including migration, 
proliferation and survival [52-55]. Pcdh12 is located at interendothelial junctions, mostly in 
angiogenic endothelium, and its function is presently unknown [22, 49]. 
 
-catenin trafficking in endothelial cells 
As described for epithelial cells, ß-catenin may translocate to the nucleus and activate 
several genes including cyclin D1 and myc whose products induce entry in the cell cycle [56]. 
During human embryonic development, ß-catenin was detected in endothelial cell nuclei 
and cytoplasms of capillaries (in particular in the brain), arteries and veins [57-59]. In 
quiescent endothelial cells of adults, ß-catenin is detectable neither in the nucleus nor in the 
cytoplasm, but appears to be concentrated at cell-cell contacts. Conversely, ß-catenin is often 
observed in the nucleus and cytoplasm of endothelial cells during pathological angiogenesis 
or vascular remodeling. Consistently, intracellular (nuclear or cytosolic, as opposed to 
junctional) accumulation of ß-catenin correlates with BrDU incorporation, which therefore 
links the presence of intracellular ß-catenin to a proliferative state. 
The conditional inactivation of ß-catenin in the endothelium leads to morphological 
alterations of vessels, increased vascular permeability and eventually results in embryonic 
lethality at mid-gestation [60, 61]. In endothelial cells devoid of ß-catenin, plakoglobin solely 
binds to VE-cadherin. As opposed to ß-catenin, plakoglobin may bind to either -catenin or 
desmoplakin and vimentin. Therefore, the VE-cadherin complex may interact more strongly 
with the vimentin cytoskeleton in this context. 
Altogether, these features suggest that physiological regulation of endothelial junctions 
depends on (i) a subtle balance between ß-catenin and plakoglobin binding to VE-cadherin 
and (ii) the proportion between intracellular and junctional ß-catenin. 
 
Regulation of VE-cadherin barrier function 
Beside its role in maintaining endothelium integrity, VE-cadherin participates in the 
control of vascular permeability and leukocyte transmigration, as documented by injection of 
VE-cadherin function blocking antibodies in the mouse [62-64]. During leukocyte 
transmigration, VE-cadherin-catenin complexes are pushed aside to facilitate diapedesis [65-
67]. An alternative mechanism has been described that implicates the degradation of VE-
cadherin molecules by various proteases, as discussed below. 
VEGF (vascular endothelial growth factor) is a pleiotropic cytokine relatively specific to 
endothelial cells or their progenitors inducing vascular permeability, cell survival or 
proliferation in a context-dependent manner [68]. In confluent endothelial cells, VEGF 
induces a rapid and transient tyrosine phosphorylation of VE-cadherin as well as ß-catenin 
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and plakoglobin [69]. These molecular events are accompanied by increased paracellular 
permeability and decreased association of the VE-cadherin complex with the cytoskeleton. 
Furthermore, VEGFR2, the receptor transducing VEGF signals in endothelial cells, interacts 
with the VE-cadherin complex, probably through ß-catenin [43, 70]. VE-cadherin tyrosine 
phosphorylation and association to VEGFR2 was confirmed in vivo in a model of 
physiological angiogenesis dependent on VEGF [71]. Src tyrosine kinase is constantly 
associated with VE-cadherin [71]. Chou et al. [72] showed that Src also associates with 
VEGFR2 and gets activated upon VEGF stimulation. Src inhibitors prevent VEGF-induced 
VE-cadherin phosphorylation, thereby indicating that Src is an obligatory mediator in this 
pathway [71]. Furthermore, Src directly phosphorylates VE-cadherin cytoplasmic domain on 
tyrosine 685 (Fig. 5A) [73]. The functional consequences of Y685 phosphorylation remain 
elusive, although a direct binding of C-terminal Src kinase (Csk) to phospho-Y685 has been 
reported (see below) [74]. Other VE-cadherin tyrosine phosphorylation sites (Y658 and 
Y731) have been described in correlation with increased permeability [75]. 
Recently, Gavard et al. [76] revealed an additional role of VEGF in VE-cadherin 
endocytosis and thus junction opening (Fig. 5B). VEGF induces the activation of the 
exchange factor Vav2 via Src. Vav2 activates Rac, which in turn activates PAK kinase, 
enabling phosphorylation of VE-cadherin cytoplasmic domain on serine 665. Phospho-S665 
VE-cadherin becomes a docking site for ß-arrestin-2, the binding of which triggers VE-
cadherin endocytosis. 
VEGF is not the sole endothelial effector inducing tyrosine phosphorylation of the VE-
cadherin complex. Other permeability factors, including histamine, tumor necrosis factor 
(TNF)-, platelet-activating factor (PAF) as well as activated neutrophils or integrin 
engagement phosphorylate VE-cadherin [77-83]. 
In quiescent vessels, VE-cadherin is in a dephosphorylated state. Several protein tyrosine 
phosphatases are associated with VE-cadherin: Dep-1 [84], VE-PTP [85], PTP- [86, 87] and 
SHP-2 [88]. VE-PTP and PTP-, two integral membrane proteins, directly interact with VE-
cadherin extracellular and intracellular domains, respectively. Both phosphatases were shown 
to dephosphorylate VE-cadherin after VEGF stimulation, leading to increased barrier 
function.  
VE-cadherin extracellular domain is highly sensitive to proteolysis and a 90 kDa-related 
protein corresponding to its extracellular domain is often detected in tissue extracts [71]. 
Whereas VE-cadherin cleavage by activated neutrophils has been a question of debate, 
some evidences indicate that proteases liberated by or at the surface of stimulated neutrophils 
[89], namely neutrophil elastase and cathepsin G [90] and probably others [91], cleave VE-
cadherin, thereby facilitating neutrophil transmigration.  
VE-cadherin degradation by matrix metalloproteinase, such as MMP-2, -7 and -9, has 
been documented in several settings, including apoptosis, diabetes and Dengue virus infection 
[92-96].  
VE-cadherin is also degraded by clathrin-dependent endocytosis and lysosomal targeting 
by a mechanism involving p120 [97-100]. P120 downregulation in endothelial cells induces a 
dramatic decrease in barrier function associated with a loss of VE-cadherin protein levels. 
P120 may thus be an intracellular regulator of VE-cadherin degradation. 
In conclusion, several pathways co-exist to reduce VE-cadherin-dependent barrier 
function: VE-cadherin/catenins complex dissociation from the cytoskeleton, VE-cadherin 
internalization, junctional movements and VE-cadherin degradation. 
 
Contact inhibition of cell proliferation as a consequence of junction formation 
The essential role of VE-cadherin in contact inhibition was revealed by two in vitro 
experiments. In a first study, Dejana’s group showed that proliferation was inhibited when 
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endothelial cells were seeded on dishes onto which the extracellular VE-cadherin domain had 
been adsorbed [101]. More recently, the same group reported that VE-cadherin-deficient 
endothelial cells had lost their contact inhibition and reached increased cell density [84].  
Several signaling pathways were identified that may explain the growth inhibition 
controlled by VE-cadherin. 
(1) VE-cadherin might sequester ß-catenin at the membrane, thereby preventing 
transcriptional activation of proliferative genes. Interestingly, a study exploited this property 
by ectopically expressing the VE-cadherin cytoplasmic domain in tumor cells, to successfully 
block ß-catenin transcriptional activity and specifically kill these cells [102]. 
(2) VE-cadherin binding to VEGFR2 leads to a dramatic decrease in VEGFR2 tyrosine 
phosphorylation [84]. Consequently, both MAP kinase activation and cellular proliferation are 
reduced. The protein tyrosine phosphatase Dep1, associated to the VE-cadherin complex, 
might be responsible for VEGFR2 dephosphorylation (Fig. 6). More recently, the mechanism 
by which VE-cadherin attenuates VEGF proliferative signal has been further deciphered 
[103]. Junctional VE-cadherin reduces VEGFR2 internalization after VEGF activation and 
decreases receptor signaling from endosomal compartments by a Dep1-dependent 
mechanism. Conversely, in sparse cells, VEGFR2 is internalized faster and its proliferative 
activity lasts longer.  
(3) VE-cadherin interacts with Shc, a protein known to activate the MAP kinase cascade, 
after stimulation with VEGF [104]. This binding leads to Shc dephosphorylation probably by 
junctional VE-cadherin-associated phosphatases. Phospho-Shc is able to couple Grb2-Sos to 
Ras, which eventually activates the MAP kinases (Fig. 6) [105]. Therefore, junctional docking 
of Shc and its subsequent dephosphorylation may inhibit VEGF proliferative activity. 
(4) The protein tyrosine kinase Csk (C-terminal Src kinase) is a negative regulator of the 
Src family kinases that inactivates these enzymes by phosphorylation of their inhibitory 
tyrosine, thereby imposing a locked conformation [106]. Analysis of chimeric embryos 
containing Csk-deficient and wild type cells revealed defects in angiogenic sprouting and 
vascular remodeling, a phenotype reminiscent of VE-cadherin-deficient embryos [107]. Csk 
binds to VE-cadherin cytoplasmic domain when Y685 is phosphorylated (Fig. 5A) [74] and 
Csk siRNA inhibition in endothelial cells increases proliferation. It is thus likely that VE-
cadherin participates in cell contact inhibition by recruitment of Csk and inhibition of Src 
activity. 
(5) Finally, by culturing endothelial cells on patterned substrates, Nelson and Chen [108] 
showed that VE-cadherin may inhibit proliferation by actively decreasing cell spreading. By 
preventing the VE-cadherin-induced change in morphology, the authors revealed that VE-
cadherin also elicit a growth signal mediated by actin cytoskeleton tension. 
 
VE-cadherin implication in VEGF survival signaling and the endothelial hemodynamic 
force response 
Quiescent endothelial cells are resistant to harmful stimuli, such as serum deprivation. 
Similar to other cadherin members, VE-cadherin protects endothelial cells from serum 
deprivation-induced apoptosis. Yet, VEGF-induced phosphorylation of PI3 kinase and 
subsequent activation of the serine-threonine kinase Akt is enhanced by VE-cadherin and its 
binding to the VEGFR2 complex (Fig. 6) [43].  
In addition, VE-cadherin induces Gas1 (growth arrest-specific 1) expression [109]. This 
protein efficiently protects cells from apoptosis. Interestingly, VE-cadherin-blocking 
antibodies prevent VEGF-induced stimulation of Gas1 expression, suggesting that junctional 
assembly of VE-cadherin is required for Gas1 induction. 
Therefore, VE-cadherin acts both as a junctional sensor and a molecular switch, directing 
VEGF signaling towards proliferation or survival. 
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Endothelial cells are also exposed to and activated by the bloodstream. Hemodynamic 
forces are variable along the vascular tree and induce a complex response in the endothelium, 
including the induction or repression of several genes as well as modifications in cell 
morphology. Junction resistance to flow stress is dependent upon VE-cadherin, and more 
specifically upon its binding to plakoglobin [110]. Furthermore, loss of VE-cadherin 
precludes transcriptional activation of a shear stress-responsive promoter. In fact, VEGFR2, 
VE-cadherin together with PECAM/CD31 form a mecanosensor complex that is sufficient to 
activate a flow-response to heterologous cells [111, 112].  
 
VE-cadherin and cytoskeleton organization through G protein activation 
Cadherins are good candidates as mediator of cytoskeletal organization modifications, 
such as those observed during epithelio-mesenchymal transition. An increasing number of 
studies indicates that cadherin engagement induces activation of Rho family GTPases.  
Rac activity is associated with endothelial junction strengthening. Yet, its inhibition 
induces endothelial junction disruption [113]. Rac may act by promoting actin polymerization 
or by coupling the VE-cadherin complex to the cytoskeleton [114].  
A recent study shows that acute hypoxia transiently inhibits Rac1, leading to RhoA 
activation, actin stress fiber formation, adherens junction opening and eventually increased 
endothelial permeability. Conversely, re-oxygenation strongly activates Rac1 and restores the 
cortical location of actin filament by inhibiting RhoA [115].  
The endothelium is separated from interstitial collagens by a basal lamina constituted by 
several proteins, including laminins. Laminin I induces a sustained activation of Rac, 
correlated with endothelial quiescence, while collagen I, to which sprouting cells are exposed, 
triggers adherens junction disruption and capillary morphogenesis associated with and 
dependent of Rho activation [116]. 
Intriguingly, a recent study reports the activation of Rac1 in VEGF-treated endothelial 
cells, which transiently prevents VEGF-induced paracellular permeability [117]. A dominant-
negative form of Rac1 abolishes the transient barrier effect, whereas the established and 
sustained effect of VEGF is unmodified. 
Numerous reports indicate that Rac activity increases the endothelial barrier. However, 
this notion was challenged by van Wetering et al. [118], who showed that expression of 
constitutively active Rac in endothelial cells caused a rapid and ROS (reactive oxygen 
species)-dependent disruption of cell junctions. The same group further demonstrated that 
activation of Rac and subsequent production of ROS resulted in ß-catenin phosphorylation by 
the tyrosine kinase Pyk2 [119]. As mentioned above, Rac also participates in VE-cadherin 
internalization after VEGF stimulation [76]. 
Altogether, these results show that Rac is involved in several signaling pathways leading 
to either endothelial barrier reinforcement or increased permeability. 
Whether it is clearly demonstrated that Rho and Rac are potent effectors of VE-cadherin 
adhesive activity, the reverse is also true. Hence, VE-cadherin re-expression in VE-cadherin-
deficient endothelial cells increases Rac activity by augmenting the expression of Rac-
specific guanosine-exchange factor Tiam1 [120]. Furthermore, VE-cadherin re-expression 
increases the membrane-associated pools of Tiam1, Rac and its effector PAK (p-21 activated 
kinase). These properties are lost when VE-cadherin lacks domains interacting with p120 or 
ß-catenin.  
VE-cadherin also regulates RhoA, which in turn transmits signals via the actin 
cytoskeleton to adhesive proteins implicated in cell-matrix attachment [108, 121]. As 
previously mentioned, following cell-cell contacts, this signaling may limit endothelial cell 
spreading. 
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Hence, VE-cadherin, by interfering with small G-protein activity, may act on 
cytoskeleton organization, cell spreading and matrix adhesion. 
The GTPase Cdc42 also controls VE-cadherin activity. Indeed, a dominant-negative 
mutant of Cdc42 dramatically decreases endothelial junction reformation, following an 
inflammatory stimulation like thrombin [122]. The same group further demonstrated that 
Cdc42 acts on adherens junctions by controlling the binding of -catenin to the ß-catenin/VE-
cadherin complex [123]. Remarkably, the cytoplasmic domain of extrajunctional VE-cadherin 
is capable to induce formation of extended membrane protrusions by a Cdc42-dependent 
mechanism [124]. Hence, Cdc42 controls VE-cadherin protrusive activity by an inside-out 
signaling pathway utilizing actin polymerization. This mechanism, together with the potent 
heterophilic adhesion of VE-cadherin with fibrin [125], may play a pivotal role in capillary 
morphogenesis.  
Cyclic AMP (cAMP) is a second messenger acting downstream of G-protein-coupled 
receptors, whose production increases endothelial barrier function [126]. Receptor agonists, 
such as prostacyclins or prostaglandins, attenuate the hyperpermeability induced by 
inflammatory stimuli [127]. A recent study shed light on the role of Rap1, a Ras family 
GTPase, in this process [128]. Elevated levels of intracellular cAMP enable the activation of 
the exchange factor Epac, which is a specific activator of Rap1. Epac or Rap1 activation 
decreases permeability by promoting the extension of VE-cadherin-based junctions (Fig. 7) 
[129]. Another report indicates that the homophilic engagement of VE-cadherin is sufficient 
to activate Rap1, by a mechanism dependent on the adaptor protein MAGI-I [130]. This 
protein, probably recruited at the junction by ß-catenin, is associated with the exchange factor 
PDZ-GEF1, which is a direct Rap1 activator (Fig. 7). Hence, first homophilic VE-cadherin 
contacts may autonomously enhance adherens junction assembly. Both the cAMP-Epac-Rap1 
and the MAGI-I-PDZ-GEF1-Rap1 pathways may interfere with VE-cadherin-based junctions 
by controlling the cortical actin cytoskeleton. 
Although the regulation mechanisms linking AJ and the cytoskeleton are probably not 
fully elucidated, it is possible to conclude that the VE-cadherin complex is an actor of 
vascular morphogenesis through actin remodeling, as well as an integrator of endothelial 
stimuli and physiological state. 
 
 
THE ENDOTHELIAL TIGHT JUNCTION 
 
TJs show considerable variability among different segments of the vascular tree [2]. This 
disparity constitutes a major evidence of vascular bed differentiation of endothelial cells and 
has a strong impact on vascular permeability and leukocyte extravasation. Variations concern 
the complexity degree of the occluding strands as well as TJ composition. 
Large artery endothelial cells, which are exposed to high flow rates, display a well-
developed system of TJ. Within the microvasculature, TJ are less complex in capillaries than 
in arterioles, and even less in venules. As previously mentioned, post-capillary venules are the 
primary site of leukocyte extravasation, and accordingly, they display a high content of 
permeability mediator receptors, such as those for histamine, serotonin and bradykinin. At the 
opposite, the blood brain barrier (BBB) and the blood retinal barrier (BRB) are particularly 
rich in TJ and endothelial TJs have been mostly studied in these locations (as reviews, see [2, 
28, 131-135]). It is currently admitted that the BBB/BRB TJ phenotype is induced by 2 
perivascular cell types: the astrocytes through their cellular processes (end foot) and the 
closely associated pericytes. Both cells produce factors, including angiopoietin-1, TGF and 
probably other uncharacterized molecules, that are required to induce the barrier phenotype 
and [136-138].  
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As discussed below, some of TJ components are specific to endothelial cells. In addition, 
the same molecules might be differentially assembled and regulated in endothelial versus 
epithelial TJs. As previously mentioned, we will concentrate herein on TJ molecules and 
mechanisms specific to endothelial cells. The general organization of TJs is described in 
chapters 2-3 and in previous reviews [28, 139]. It should be noted that information regarding 
TJ component properties mostly derives from studies on epithelial cells because of lack of 
convenient endothelial cell models retaining TJ. 
 
Claudins, occludin and the submembrane TJ complex 
Claudin family members are the major TJ transmembrane constituents, exhibiting 
homophilic and heterophilic (with other claudin subtypes) adhesive activities through their 
extracellular domains and forming the TJ strands [135]. As previously mentioned, endothelial 
TJs specifically and highly express claudin-5, with a few exceptions [140]. Claudin-5-
deficient mice have selective impairment in BBB function for molecules smaller than 800 Da 
[141]. This phenotype suggests a partial redundancy between claudin subtypes. Yet, claudin-3 
and -11 have also been characterized in endothelial cells [142-145]. Initial identification of 
claudin-1 and -12 [141, 146] in the endothelium is now largely questioned and was not 
confirmed. Beside their barrier function, claudins also behave as specific channels and their 
diversity reflects their differential function in paracellular transport [147]. A number of 
pathological settings associated with decreased BBB function were correlated with lower 
claudin expression, thereby indicating that claudins may be therapeutic targets in brain edema 
lesions [144, 146, 148-152]. 
Another transmembrane component of TJ strands is occludin. Although not necessary for 
TJ strand formation, occludin is associated with increased TJ barrier function. In the 
endothelium, this molecule is specifically expressed in the BBB and the BRB [12] and its 
expression is increased with pericyte-derived angiopoietin-1 [136]. Whereas occludin 
downregulation has been observed in various disease state associated with BBB or BRB 
disruption, including stroke, diabetes as well as hypoxia/aglycemia [153-158]. Nevertheless, 
the fact that genetic ablation of occludin does not affect endothelial TJ organization or 
permeability is intriguing and may indicate differential functions in man and mouse [159].  
Decreased occludin contents together with increased paracellular permeability were 
observed in VEGF-treated retinal endothelial cells by a proteolytic mechanism depending on 
urokinase plasminogen activator (Fig. 8) [153, 160]. Occludin proteolysis by 
metalloproteinases was also observed after protein tyrosine phosphatase inhibition or 
monocyte diapedesis [161, 162]. These features suggest that occludin degradation may be one 
of the mechanisms increasing vascular permeability. VEGF activation also leads to occludin 
phosphorylation on serine/threonine residues through PKC activation in correlation with 
increased permeability (Fig. 8) [163, 164]. Upon VEGF treatment, occludin is phosphorylated 
on multiple serine and threonine residues, however the identification of the precise 
phosphorylation sites and their molecular function remain elusive [154]. Other factors, 
namely lysophosphatidic acid, histamine, oxidized phospholipids, monocyte chemoattractant 
protein-1 (MCP-1 or CCL-2) or shear-stress, induce both occludin phosphorylation on 
serine/threonine residues and increased permeability (Fig. 8) [165-168]. But paradoxically, 
angiotensin-2 was shown to increase blood brain barrier function in correlation with increased 
threonine phosphorylation of occludin together with its mobilization to lipid rafts (Fig. 8) 
[169]. Thus, the functional consequences of occludin phosphorylation may be phospho-site-
dependent. Stamatovic et al. [168] demonstrated that MCP-1, in addition to occludin, also 
targets ZO-1, ZO-2 (see below) and claudin-5 phosphorylation on serine/threonine residues 
by a signaling pathway involving Rho and PKC. Occludin may also be phosphorylated on 
tyrosine residues following cerebral ischemia and angiotensin-2 has a negative impact on 
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occludin tyrosine phosphorylation level (Fig. 8) [168, 170]. In conclusion, inflammatory or 
angiogenic mediators alter BBB function in part by acting on occludin integrity, localization 
or phosphorylation level. Conversely, hydrocortisone treatment, through its anti-inflammatory 
properties, increased occludin levels and barrier properties of retinal endothelial cells [171].  
Claudins and occludin are linked to numerous intracellular partners, including ZO-1, -2 
and -3, AF-6/afadin, PAR-3, cingulin and 7H6 antigen, also present in epithelial TJs [28]. 
These proteins form a molecular complex at the submembrane side of TJs. Detailed properties 
of these proteins and their molecular interactions are reviewed in other chapters and reviews 
[149]. Interestingly, two versions of ZO-1 resulting from alternative splicing may be found. 
An 80 amino-acid domain, called , may be inserted in the central part of the protein. 
Whereas the ZO-1+ variant is found in most epithelial cells, the ZO-1- isoform is only 
observed in endothelial cells, Sertoli cells and podocytes of kidney glomeruli [172-174]. In 
general, the ZO-1- isoform characterizes more dynamic junctions. Symplekin, another 
protein located in the TJ complex of some epithelia, is absent in endothelial cells [175].  
 
The JAMs 
JAM-A, -B, and -C constitute a family of transmembrane adhesive proteins belonging to 
Ig superfamily that colocalize with TJ, although not included in TJ strands [20]. Of note, 
JAM-B localization at TJ has been challenged [176]. JAM-A is located in epithelial and 
endothelial intercellular junctions and at the surface of platelets and leukocytes [13, 177], 
while JAM-C expression is restricted to endothelial cells of lymphatic sinuses and high 
endothelial venules of lymphatic organs, as well as smooth muscle cells, fibroblasts and some 
blood cells; however its tissue distribution varies between mouse and human (see [178] and 
references therein and [179]). JAM-B is expressed at interendothelial junctions [180] but its 
tissue distribution is less documented than the two other members.  
JAM-A develops homophilic adhesive activity, suggesting that it may mediate 
endothelial cell-cell interaction. Its barrier function is further demonstrated by use of blocking 
antibodies or peptides [181, 182]. Furthermore, the presence of JAM-A at intercellular 
junctions reduces paracellular permeability [13]. Intracellularly, it interacts with several 
members of TJ complex (see [183], for more details), as well as the PAR-3/aPKC/PAR-6 
polarity complex, suggesting that JAM-A may be involved in the establishment of apical-
basal polarity. Most recent studies on JAM-A are focused on its role in leukocyte 
transmigration. In inflammatory conditions, JAM-A is redistributed at the apical surface [184, 
185]. JAM-A, together with PECAM, CD99 [20] and other JAMs (see below), facilitates 
leukocyte transmigration through the intercellular cleft. During diapedesis, JAM-A binds 
heterophilically to Lß2 integrin located on leukocytes [186]. The phenotype of JAM-A-
deficient mice confirmed its activity in neutrophil transmigration and unveiled other functions 
including the restriction of dendritic cell trafficking in lymph nodes or its participation in 
bFGF-induced angiogenesis [187-190].  
JAM-C develops homophilic binding at interendothelial junctions, where it may also 
interact, even with higher affinity, with JAM-B [191, 192]. As opposed to JAM-A, junctional 
localization of JAM-C increases paracellular permeability, possibly by modulating VE-
cadherin cell-cell contacts [176, 193]. JAM-C promotes neutrophil transmigration via its 
binding to the leukocyte integrin Mß2 [192], but this activity is lost under shear-stress 
conditions, suggesting a weak interaction [194]. Two reports indicate that tumor cells also 
express JAM-C at their surface [195, 196]; this feature may promote the metastatic potential 
of these cells by facilitating their adhesion to endothelial cells via homophilic binding and 
their subsequent transmigration. JAM-C also regulates tumor cell migration by regulating 
integrin activity [197]. JAM-C-deficient mice exhibit growth retardation and pneumonia 
causing poor survival of the mice [198]. Additionally, the number of circulating granulocytes 
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is increased, which seems to be caused by loss of endothelial JAM-C as its rescue in 
endothelial cells is sufficient to restore homeostasis and better survival.  
ESAM is a transmembrane Ig protein related to JAMs [18]. Its expression is restricted to 
endothelial cell TJs and to the surface of activated platelets. ESAM mediates homophilic 
binding and its only known cytoplasmic binding partner is MAGI-I [199]. ESAM-deficient 
mice showed defective tumor angiogenesis, whereas physiological angiogenesis was normal 
[200]. Endothelial ESAM also participates in neutrophil extravasation by a mechanism 
involving Rho activation and TJ destabilization [201].  
Collectively, these data indicate that JAM/ESAM family members have pivotal and 
selective functions in leukocyte trafficking and may also influence TJ dynamics. 
 
Nectins 
Nectins form another group of cell-cell adhesion molecules belonging to the Ig 
superfamily [15, 202, 203]. Four members have been described, nectin 1-4, as well as five 
nectin-like molecules, Necl 1-5. Nectin C-terminus interacts with the PDZ domain of 
afadin/AF-6, an actin filament-binding protein, which connects them to the actin cytoskeleton 
(Fig. 4). Nectin/afadin were found associated with TJ and AJ proteins. They participate in the 
initial step of junction formation and play a fundamental role in the establishment of polarity. 
The nectin-like molecules do not exhibit a PDZ-binding motif and do not interact with afadin.  
So far, only nectin-2 and Necl-5 were identified in endothelial cells [14, 204]. Nectin-2 is 
an -herpes receptor and Necl-5 is the poliovirus receptor [202] and thus both receptors may 
be involved in viral dissemination. Nectin-2 develop homophilic as well as heterophilic 
interactions with nectin-3, while Necl-5 does not develop homophilic binding but interacts 
with nectin-3 [15]. Necl-5 is a potential receptor for DNAM-1/CD226, a transmembrane 
glycoprotein expressed on a subset of B cells and all T cells, natural killer cells, monocytes 
and platelets. Necl-5 facilitates monocyte transmigration through endothelial monolayers and 
may thus participates in inflammatory processes in vivo. Nectin-2, which is also a DNAM-1 
ligand in other cell types, does not seem to play a similar role in endothelial cells [14].  
 
FUTURE DIRECTIONS 
In the recent years, the number of adhesive proteins at interendothelial junctions has 
stabilized and their contribution to barrier function has been relatively well established. 
Nevertheless, a comprehensive view of the proteins located on the cytoplasmic side of AJ and 
TJ is still missing. For example, after years of investigation, the molecular link between the 
actin cytoskeleton and the AJ remains elusive. The molecular network in both junction types 
is probably more complex and variable according to location and pathophysiological state 
than hitherto thought. A number of endothelial adhesive proteins are implicated in leukocyte 
adhesion and transmigration; their specific and sequential actions in these processes remain to 
be clarified. Finally, some of these proteins have demonstrated function in angiogenesis or 
cell migration through mechanisms that need to be fully investigated. 
 
ACKNOWLDEGEMENTS 
YW was supported by grants from the Rhône-Alpes regional council. 
13 
REFERENCES 
 [1] J.A.G. Rhodin, Histology, Oxford University Press, New York, 1974. 
[2] W.W. Franke, P. Cowin, C. Grund, C. Kuhn, H.P. Kapprell, The endothelial junction: 
the plaque and its component., in: N. Simionescu, M. Simionescu (Eds.), Endothelial 
cell biology in health and diseases, Plenum publishing corporation, New York, 1988, 
pp. 147-166. 
[3] M. Schmelz, W.W. Franke, Complexus adhaerentes, a new group of desmoplakin-
containing junctions in endothelial cells: the syndesmos connecting retothelial cells of 
lymph nodes, Eur J Cell Biol 61 (1993) 274-289. 
[4] M. Schmelz, R. Moll, C. Kuhn, W.W. Franke, Complexus adhaerentes, a new group 
of desmoplakin-containing junctions in endothelial cells: II. Different types of 
lymphatic vessels, Differentiation; research in biological diversity 57 (1994) 97-117. 
[5] A.P. Kowalczyk, P. Navarro, E. Dejana, E.A. Bornslaeger, K.J. Green, D.S. Kopp, 
J.E. Borgwardt, VE-cadherin and desmoplakin are assembled into dermal 
microvascular endothelial intercellular junctions: a pivotal role for plakoglobin in the 
recruitment of desmoplakin to intercellular junctions, J Cell Sci 111 (1998) 3045-
3057. 
[6] K. Venkiteswaran, K. Xiao, S. Summers, C.C. Calkins, P.A. Vincent, K. Pumiglia, 
A.P. Kowalczyk, Regulation of endothelial barrier function and growth by VE-
cadherin, plakoglobin, and beta-catenin, Am J Physiol Cell Physiol 283 (2002) C811-
821. 
[7] C.C. Calkins, B.L. Hoepner, C.M. Law, M.R. Novak, S.V. Setzer, M. Hatzfeld, A.P. 
Kowalczyk, The Armadillo family protein p0071 is a VE-cadherin- and desmoplakin-
binding protein, J Biol Chem 278 (2003) 1774-1783. 
[8] B. Hammerling, C. Grund, J. Boda-Heggemann, R. Moll, W.W. Franke, The 
complexus adhaerens of mammalian lymphatic endothelia revisited: a junction even 
more complex than hitherto thought, Cell and tissue research 324 (2006) 55-67. 
[9] M.G. Lampugnani, M. Resnati, M. Raiteri, R. Pigott, A. Pisacane, G. Houen, L.P. 
Ruco, E. Dejana, A novel endothelial-specific membrane protein is a marker of cell-
cell contacts, J Cell Biol 118 (1992) 1511-1522. 
[10] G. Breier, F. Breviario, L. Caveda, R. Berthier, H. Schnurch, U. Gotsch, D. 
Vestweber, W. Risau, E. Dejana, Molecular cloning and expression of murine vascular 
endothelial- cadherin in early stage development of cardiovascular system, Blood 87 
(1996) 630-641. 
[11] K. Morita, H. Sasaki, M. Furuse, S. Tsukita, Endothelial claudin: claudin-5/TMVCF 
constitutes tight junction strands in endothelial cells, J Cell Biol 147 (1999) 185-194. 
[12] T. Hirase, J.M. Staddon, M. Saitou, Y. Ando-Akatsuka, M. Itoh, M. Furuse, K. 
Fujimoto, S. Tsukita, L.L. Rubin, Occludin as a possible determinant of tight junction 
permeability in endothelial cells, J Cell Sci 110 ( Pt 14) (1997) 1603-1613. 
[13] I. Martin-Padura, S. Lostaglio, M. Schneemann, L. Williams, M. Romano, P. 
Fruscella, C. Panzeri, A. Stoppacciaro, L. Ruco, A. Villa, D. Simmons, E. Dejana, 
Junctional adhesion molecule, a novel member of the immunoglobulin superfamily 
that distributes at intercellular junctions and modulates monocyte transmigration, J 
Cell Biol 142 (1998) 117-127. 
[14] N. Reymond, A.M. Imbert, E. Devilard, S. Fabre, C. Chabannon, L. Xerri, C. 
Farnarier, C. Cantoni, C. Bottino, A. Moretta, P. Dubreuil, M. Lopez, DNAM-1 and 
PVR regulate monocyte migration through endothelial junctions, The Journal of 
experimental medicine 199 (2004) 1331-1341. 
[15] H. Ogita, Y. Takai, Nectins and nectin-like molecules: roles in cell adhesion, 
polarization, movement, and proliferation, IUBMB life 58 (2006) 334-343. 
14 
[16] C. de Wit, S.E. Wolfle, B. Hopfl, Connexin-dependent communication within the 
vascular wall: contribution to the control of arteriolar diameter, Advances in 
cardiology 42 (2006) 268-283. 
[17] P.J. Newman, The biology of PECAM-1, J Clin Invest 99 (1997) 3-8. 
[18] K. Hirata, T. Ishida, K. Penta, M. Rezaee, E. Yang, J. Wohlgemuth, T. Quertermous, 
Cloning of an immunoglobulin family adhesion molecule selectively expressed by 
endothelial cells, J Biol Chem 276 (2001) 16223-16231. 
[19] I. Nasdala, K. Wolburg-Buchholz, H. Wolburg, A. Kuhn, K. Ebnet, G. Brachtendorf, 
U. Samulowitz, B. Kuster, B. Engelhardt, D. Vestweber, S. Butz, A transmembrane 
tight junction protein selectively expressed on endothelial cells and platelets, J Biol 
Chem 277 (2002) 16294-16303. 
[20] W.A. Muller, Leukocyte-endothelial-cell interactions in leukocyte transmigration and 
the inflammatory response, Trends Immunol 24 (2003) 327-334. 
[21] N. Bardin, F. Anfosso, J.M. Masse, E. Cramer, F. Sabatier, A. Le Bivic, J. Sampol, F. 
Dignat-George, Identification of CD146 as a component of the endothelial junction 
involved in the control of cell-cell cohesion, Blood 98 (2001) 3677-3684. 
[22] C. Rampon, M.H. Prandini, S. Bouillot, H. Pointu, E. Tillet, R. Frank, M. Vernet, P. 
Huber, Protocadherin 12 (VE-cadherin 2) is expressed in endothelial, trophoblast, and 
mesangial cells, Exp Cell Res 302 (2005) 48-60. 
[23] M.G. Lampugnani, M. Corada, L. Caveda, F. Breviario, O. Ayalon, B. Geiger, E. 
Dejana, The molecular organization of endothelial cell to cell junctions: differential 
association of plakoglobin, beta-catenin, and alpha- catenin with vascular endothelial 
cadherin (VE-cadherin), J Cell Biol 129 (1995) 203-217. 
[24] P. Panorchan, J.P. George, D. Wirtz, Probing intercellular interactions between 
vascular endothelial cadherin pairs at single-molecule resolution and in living cells, J 
Mol Biol 358 (2006) 665-674. 
[25] P. Legrand, S. Bibert, M. Jaquinod, C. Ebel, E. Hewat, F. Vincent, C. Vanbelle, E. 
Concord, T. Vernet, D. Gulino, Self-assembly of the vascular endothelial cadherin 
ectodomain in a Ca2+-dependent hexameric structure, J Biol Chem 276 (2001) 3581-
3588. 
[26] S. Bibert, M. Jaquinod, E. Concord, C. Ebel, E. Hewat, C. Vanbelle, P. Legrand, M. 
Weidenhaupt, T. Vernet, D. Gulino-Debrac, Synergy between extracellular modules of 
vascular endothelial cadherin promotes homotypic hexameric interactions, J Biol 
Chem 277 (2002) 12790-12801. 
[27] E.A. Hewat, C. Durmort, L. Jacquamet, E. Concord, D. Gulino-Debrac, Architecture 
of the VE-cadherin hexamer, J Mol Biol 365 (2007) 744-751. 
[28] G. Bazzoni, E. Dejana, Endothelial cell-to-cell junctions: molecular organization and 
role in vascular homeostasis, Physiol Rev 84 (2004) 869-901. 
[29] S. Yamada, S. Pokutta, F. Drees, W.I. Weis, W.J. Nelson, Deconstructing the 
cadherin-catenin-actin complex, Cell 123 (2005) 889-901. 
[30] S. Iden, D. Rehder, B. August, A. Suzuki, K. Wolburg-Buchholz, H. Wolburg, S. 
Ohno, J. Behrens, D. Vestweber, K. Ebnet, A distinct PAR complex associates 
physically with VE-cadherin in vertebrate endothelial cells, EMBO reports 7 (2006) 
1239-1246. 
[31] H. Delanoe-Ayari, R. Al Kurdi, M. Vallade, D. Gulino-Debrac, D. Riveline, 
Membrane and acto-myosin tension promote clustering of adhesion proteins, Proc 
Natl Acad Sci U S A 101 (2004) 2229-2234. 
[32] O. Lambert, J.C. Taveau, J.L. Him, R. Al Kurdi, D. Gulino-Debrac, A. Brisson, The 
basic framework of VE-cadherin junctions revealed by cryo-EM, J Mol Biol 346 
(2005) 1193-1196. 
15 
[33] Y. Zhou, S.J. Fisher, M. Janatpour, O. Genbacev, E. Dejana, M. Wheelock, C.H. 
Damsky, Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A 
strategy for successful endovascular invasion?, J Clin Invest 99 (1997) 2139-2151. 
[34] M.J. Hendrix, E.A. Seftor, P.S. Meltzer, L.M. Gardner, A.R. Hess, D.A. Kirschmann, 
G.C. Schatteman, R.E. Seftor, Expression and functional significance of VE-cadherin 
in aggressive human melanoma cells: role in vasculogenic mimicry, Proc Natl Acad 
Sci U S A 98 (2001) 8018-8023. 
[35] M. Peichev, A.J. Naiyer, D. Pereira, Z. Zhu, W.J. Lane, M. Williams, M.C. Oz, D.J. 
Hicklin, L. Witte, M.A. Moore, S. Rafii, Expression of VEGFR-2 and AC133 by 
circulating human CD34(+) cells identifies a population of functional endothelial 
precursors, Blood 95 (2000) 952-958. 
[36] C.D. Cohen, A. Klingenhoff, A. Boucherot, A. Nitsche, A. Henger, B. Brunner, H. 
Schmid, M. Merkle, M.A. Saleem, K.P. Koller, T. Werner, H.J. Grone, P.J. Nelson, 
M. Kretzler, Comparative promoter analysis allows de novo identification of 
specialized cell junction-associated proteins, Proc Natl Acad Sci U S A 103 (2006) 
5682-5687. 
[37] P. Huber, J. Dalmon, J. Engiles, F. Breviario, S. Gory, L.D. Siracusa, A.M. Buchberg, 
E. Dejana, Genomic structure and chromosomal mapping of the mouse VE-cadherin 
gene (Cdh5), Genomics 32 (1996) 21-28. 
[38] S. Gory, J. Dalmon, M.H. Prandini, T. Kortulewski, Y. de Launoit, P. Huber, 
Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial 
cadherin gene transcription, J Biol Chem 273 (1998) 6750-6755. 
[39] E. Lelievre, V. Mattot, P. Huber, B. Vandenbunder, F. Soncin, ETS1 lowers capillary 
endothelial cell density at confluence and induces the expression of VE-cadherin, 
Oncogene 19 (2000) 2438-2446. 
[40] V. Deleuze, E. Chalhoub, R. El-Hajj, C. Dohet, M. Le Clech, P.O. Couraud, P. Huber, 
D. Mathieu, TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin 
expression in endothelial cells, Mol Cell Biol 27 (2007) 2687-2697. 
[41] M.H. Prandini, I. Dreher, S. Bouillot, S. Benkerri, T. Moll, P. Huber, The human VE-
cadherin promoter is subjected to organ-specific regulation and is activated in tumour 
angiogenesis, Oncogene 24 (2005) 2992-3001. 
[42] S. Gory-Fauré, M.H. Prandini, H. Pointu, V. Roullot, I. Pignot-Paintrand, M. Vernet, 
P. Huber, Role of vascular endothelial-cadherin in vascular morphogenesis, 
Development 126 (1999) 2093-2102. 
[43] P. Carmeliet, M.G. Lampugnani, L. Moons, F. Breviario, V. Compernolle, F. Bono, G. 
Balconi, R. Spagnuolo, B. Oostuyse, M. Dewerchin, A. Zanetti, A. Angellilo, V. 
Mattot, D. Nuyens, E. Lutgens, F. Clotman, M.C. de Ruiter, A. Gittenberger-de Groot, 
R. Poelmann, F. Lupu, J.M. Herbert, D. Collen, E. Dejana, Targeted deficiency or 
cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated 
endothelial survival and angiogenesis, Cell 98 (1999) 147-157. 
[44] M. Corada, L. Zanetta, F. Orsenigo, F. Breviario, M.G. Lampugnani, S. Bernasconi, F. 
Liao, D.J. Hicklin, P. Bohlen, E. Dejana, A monoclonal antibody to vascular 
endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial 
permeability, Blood 100 (2002) 905-911. 
[45] F. Liao, J.F. Doody, J. Overholser, B. Finnerty, R. Bassi, Y. Wu, E. Dejana, P. Kussie, 
P. Bohlen, D.J. Hicklin, Selective targeting of angiogenic tumor vasculature by 
vascular endothelial-cadherin antibody inhibits tumor growth without affecting 
vascular permeability, Cancer Res 62 (2002) 2567-2575. 
[46] C. May, J.F. Doody, R. Abdullah, P. Balderes, X. Xu, C.P. Chen, Z. Zhu, L. Shapiro, 
P. Kussie, D.J. Hicklin, F. Liao, P. Bohlen, Identification of a transiently exposed VE-
16 
cadherin epitope that allows for specific targeting of an antibody to the tumor 
neovasculature, Blood 105 (2005) 4337-4344. 
[47] D. Salomon, O. Ayalon, R. Patel-King, R.O. Hynes, B. Geiger, Extrajunctional 
distribution of N-cadherin in cultured human endothelial cells, J Cell Sci 102 (1992) 
7-17. 
[48] D. Ivanov, M. Philippova, J. Antropova, F. Gubaeva, O. Iljinskaya, E. Tararak, V. 
Bochkov, P. Erne, T. Resink, V. Tkachuk, Expression of cell adhesion molecule T-
cadherin in the human vasculature, Histochemistry and cell biology 115 (2001) 231-
242. 
[49] P. Telo, F. Breviario, P. Huber, C. Panzeri, E. Dejana, Identification of a novel 
cadherin (vascular endothelial cadherin-2) located at intercellular junctions in 
endothelial cells, J Biol Chem 273 (1998) 17565-17572. 
[50] H. Gerhardt, H. Wolburg, C. Redies, N-cadherin mediates pericytic-endothelial 
interaction during brain angiogenesis in the chicken, Dev Dyn 218 (2000) 472-479. 
[51] E. Tillet, D. Vittet, O. Feraud, R. Moore, R. Kemler, P. Huber, N-cadherin deficiency 
impairs pericyte recruitment, and not endothelial differentiation or sprouting, in 
embryonic stem cell-derived angiogenesis, Exp Cell Res 310 (2005) 392-400. 
[52] D. Ivanov, M. Philippova, R. Allenspach, P. Erne, T. Resink, T-cadherin upregulation 
correlates with cell-cycle progression and promotes proliferation of vascular cells, 
Cardiovasc Res 64 (2004) 132-143. 
[53] D. Ivanov, M. Philippova, V. Tkachuk, P. Erne, T. Resink, Cell adhesion molecule T-
cadherin regulates vascular cell adhesion, phenotype and motility, Exp Cell Res 293 
(2004) 207-218. 
[54] M.B. Joshi, M. Philippova, D. Ivanov, R. Allenspach, P. Erne, T.J. Resink, T-cadherin 
protects endothelial cells from oxidative stress-induced apoptosis, Faseb J 19 (2005) 
1737-1739. 
[55] M. Philippova, D. Ivanov, V. Tkachuk, P. Erne, T.J. Resink, Polarisation of T-
cadherin to the leading edge of migrating vascular cells in vitro: a function in vascular 
cell motility?, Histochemistry and cell biology 120 (2003) 353-360. 
[56] A.M. Goodwin, P.A. D'Amore, Wnt signaling in the vasculature, Angiogenesis 5 
(2002) 1-9. 
[57] C.G. Eberhart, P. Argani, Wnt signaling in human development: beta-catenin nuclear 
translocation in fetal lung, kidney, placenta, capillaries, adrenal, and cartilage, Pediatr 
Dev Pathol 4 (2001) 351-357. 
[58] C.G. Eberhart, T. Tihan, P.C. Burger, Nuclear localization and mutation of beta-
catenin in medulloblastomas, Journal of neuropathology and experimental neurology 
59 (2000) 333-337. 
[59] W.M. Blankesteijn, M.E. van Gijn, Y.P. Essers-Janssen, M.J. Daemen, J.F. Smits, 
Beta-catenin, an inducer of uncontrolled cell proliferation and migration in 
malignancies, is localized in the cytoplasm of vascular endothelium during 
neovascularization after myocardial infarction, Am J Pathol 157 (2000) 877-883. 
[60] S. Liebner, A. Cattelino, R. Gallini, N. Rudini, M. Iurlaro, S. Piccolo, E. Dejana, Beta-
catenin is required for endothelial-mesenchymal transformation during heart cushion 
development in the mouse, J Cell Biol 166 (2004) 359-367. 
[61] A. Cattelino, S. Liebner, R. Gallini, A. Zanetti, G. Balconi, A. Corsi, P. Bianco, H. 
Wolburg, R. Moore, B. Oreda, R. Kemler, E. Dejana, The conditional inactivation of 
the beta-catenin gene in endothelial cells causes a defective vascular pattern and 
increased vascular fragility, J Cell Biol 162 (2003) 1111-1122. 
[62] M. Corada, F. Liao, M. Lindgren, M.G. Lampugnani, F. Breviario, R. Frank, W.A. 
Muller, D.J. Hicklin, P. Bohlen, E. Dejana, Monoclonal antibodies directed to 
17 
different regions of vascular endothelial cadherin extracellular domain affect adhesion 
and clustering of the protein and modulate endothelial permeability, Blood 97 (2001) 
1679-1684. 
[63] M. Corada, M. Mariotti, G. Thurston, K. Smith, R. Kunkel, M. Brockhaus, M.G. 
Lampugnani, I. Martin-Padura, A. Stoppacciaro, L. Ruco, D.M. McDonald, P.A. 
Ward, E. Dejana, Vascular endothelial-cadherin is an important determinant of 
microvascular integrity in vivo, Proc Natl Acad Sci U S A 96 (1999) 9815-9820. 
[64] U. Gotsch, E. Borges, R. Bosse, E. Boggemeyer, M. Simon, H. Mossmann, D. 
Vestweber, VE-cadherin antibody accelerates neutrophil recruitment in vivo, J Cell 
Sci 110 (1997) 583-588. 
[65] J.R. Allport, W.A. Muller, F.W. Luscinskas, Monocytes induce reversible focal 
changes in vascular endothelial cadherin complex during transendothelial migration 
under flow, J Cell Biol 148 (2000) 203-216. 
[66] S.K. Shaw, P.S. Bamba, B.N. Perkins, F.W. Luscinskas, Real-time imaging of 
vascular endothelial-cadherin during leukocyte transmigration across endothelium, J 
Immunol 167 (2001) 2323-2330. 
[67] W.H. Su, H.I. Chen, C.J. Jen, Differential movements of VE-cadherin and PECAM-1 
during transmigration of polymorphonuclear leukocytes through human umbilical vein 
endothelium, Blood 100 (2002) 3597-3603. 
[68] U. Eriksson, K. Alitalo, Structure, expression and receptor-binding properties of novel 
vascular endothelial growth factors, Current topics in microbiology and immunology 
237 (1999) 41-57. 
[69] S. Esser, M.G. Lampugnani, M. Corada, E. Dejana, W. Risau, Vascular endothelial 
growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells, J 
Cell Sci 111 (1998) 1853-1865. 
[70] S. Weis, S. Shintani, A. Weber, R. Kirchmair, M. Wood, A. Cravens, H. McSharry, A. 
Iwakura, Y.S. Yoon, N. Himes, D. Burstein, J. Doukas, R. Soll, D. Losordo, D. 
Cheresh, Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue 
injury following myocardial infarction, J Clin Invest 113 (2004) 885-894. 
[71] N. Lambeng, Y. Wallez, C. Rampon, F. Cand, G. Christe, D. Gulino-Debrac, I. 
Vilgrain, P. Huber, Vascular endothelial-cadherin tyrosine phosphorylation in 
angiogenic and quiescent adult tissues, Circ Res 96 (2005) 384-391. 
[72] M.T. Chou, J. Wang, D.J. Fujita, Src kinase becomes preferentially associated with the 
VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells, BMC 
Biochem 3 (2002) 32. 
[73] Y. Wallez, F. Cand, F. Cruzalegui, C. Wernstedt, S. Souchelnytskyi, I. Vilgrain, P. 
Huber, Src kinase phosphorylates vascular endothelial-cadherin in response to 
vascular endothelial growth factor: identification of tyrosine 685 as the unique target 
site, Oncogene 26 (2007) 1067-1077. 
[74] U. Baumeister, R. Funke, K. Ebnet, H. Vorschmitt, S. Koch, D. Vestweber, 
Association of Csk to VE-cadherin and inhibition of cell proliferation, Embo J 24 
(2005) 1686-1695. 
[75] M.D. Potter, S. Barbero, D.A. Cheresh, Tyrosine phosphorylation of VE-cadherin 
prevents binding of p120- and {beta}-catenin and maintains the cellular mesenchymal 
state, J Biol Chem 280 (2005) 31906-31912. 
[76] J. Gavard, J.S. Gutkind, VEGF controls endothelial-cell permeability by promoting 
the beta-arrestin-dependent endocytosis of VE-cadherin, Nature cell biology 8 (2006) 
1223-1234. 
18 
[77] P. Andriopoulou, P. Navarro, A. Zanetti, M.G. Lampugnani, E. Dejana, Histamine 
induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions, 
Arterioscler Thromb Vasc Biol 19 (1999) 2286-2297. 
[78] D.M. Shasby, D.R. Ries, S.S. Shasby, M.C. Winter, Histamine stimulates 
phosphorylation of adherens junction proteins and alters their link to vimentin, Am J 
Physiol Lung Cell Mol Physiol 282 (2002) L1330-1338. 
[79] F.E. Nwariaku, Z. Liu, X. Zhu, R.H. Turnage, G.A. Sarosi, L.S. Terada, Tyrosine 
phosphorylation of vascular endothelial cadherin and the regulation of microvascular 
permeability, Surgery 132 (2002) 180-185. 
[80] D.J. Angelini, S.W. Hyun, D.N. Grigoryev, P. Garg, P. Gong, I.S. Singh, A. Passaniti, 
J.D. Hasday, S.E. Goldblum, TNF-alpha increases tyrosine phosphorylation of 
vascular endothelial cadherin and opens the paracellular pathway through fyn 
activation in human lung endothelia, Am J Physiol Lung Cell Mol Physiol 291 (2006) 
L1232-1245. 
[81] J.H. Tinsley, M.H. Wu, W. Ma, A.C. Taulman, S.Y. Yuan, Activated neutrophils 
induce hyperpermeability and phosphorylation of adherens junction proteins in 
coronary venular endothelial cells, J Biol Chem 274 (1999) 24930-24934. 
[82] H. Hudry-Clergeon, D. Stengel, E. Ninio, I. Vilgrain, Platelet-activating factor 
increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its 
association with the PtdIns3'-kinase, Faseb J 19 (2005) 512-520. 
[83] Y. Wang, G. Jin, H. Miao, J.Y. Li, S. Usami, S. Chien, Integrins regulate VE-cadherin 
and catenins: dependence of this regulation on Src, but not on Ras, Proc Natl Acad Sci 
U S A 103 (2006) 1774-1779. 
[84] M.G. Lampugnani, A. Zanetti, M. Corada, T. Takahashi, G. Balconi, F. Breviario, F. 
Orsenigo, A. Cattelino, R. Kemler, T.O. Daniel, E. Dejana, Contact inhibition of 
VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and 
the phosphatase DEP-1/CD148, J Cell Biol 161 (2003) 793-804. 
[85] R. Nawroth, G. Poell, A. Ranft, S. Kloep, U. Samulowitz, G. Fachinger, M. Golding, 
D.T. Shima, U. Deutsch, D. Vestweber, VE-PTP and VE-cadherin ectodomains 
interact to facilitate regulation of phosphorylation and cell contacts, Embo J 24 (2005) 
3158. 
[86] C. Bianchi, F.W. Sellke, R.L. Del Vecchio, N.K. Tonks, B.G. Neel, Receptor-type 
protein-tyrosine phosphatase mu is expressed in specific vascular endothelial beds in 
vivo, Exp Cell Res 248 (1999) 329-338. 
[87] X.F. Sui, T.D. Kiser, S.W. Hyun, D.J. Angelini, R.L. Del Vecchio, B.A. Young, J.D. 
Hasday, L.H. Romer, A. Passaniti, N.K. Tonks, S.E. Goldblum, Receptor protein 
tyrosine phosphatase micro regulates the paracellular pathway in human lung 
microvascular endothelia, Am J Pathol 166 (2005) 1247-1258. 
[88] J.A. Ukropec, M.K. Hollinger, S.M. Salva, M.J. Woolkalis, SHP2 association with 
VE-cadherin complexes in human endothelial cells is regulated by thrombin, J Biol 
Chem 275 (2000) 5983-5986. 
[89] D. Carden, F. Xiao, C. Moak, B.H. Willis, S. Robinson-Jackson, S. Alexander, 
Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial 
cadherins, Am J Physiol 275 (1998) H385-392. 
[90] B. Hermant, S. Bibert, E. Concord, B. Dublet, M. Weidenhaupt, T. Vernet, D. Gulino-
Debrac, Identification of proteases involved in the proteolysis of vascular endothelium 
cadherin during neutrophil transmigration, J Biol Chem 278 (2003) 14002-14012. 
[91] J.R. Allport, Y.C. Lim, J.M. Shipley, R.M. Senior, S.D. Shapiro, N. Matsuyoshi, D. 
Vestweber, F.W. Luscinskas, Neutrophils from MMP-9- or neutrophil elastase-
19 
deficient mice show no defect in transendothelial migration under flow in vitro, 
Journal of leukocyte biology 71 (2002) 821-828. 
[92] B. Herren, B. Levkau, E.W. Raines, R. Ross, Cleavage of beta-catenin and 
plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a 
role for caspases and metalloproteinases, Mol Biol Cell 9 (1998) 1589-1601. 
[93] Y. Ichikawa, T. Ishikawa, N. Momiyama, M. Kamiyama, H. Sakurada, R. Matsuyama, 
S. Hasegawa, T. Chishima, Y. Hamaguchi, S. Fujii, S. Saito, K. Kubota, S. Hasegawa, 
H. Ike, S. Oki, H. Shimada, Matrilysin (MMP-7) degrades VE-cadherin and 
accelerates accumulation of beta-catenin in the nucleus of human umbilical vein 
endothelial cells, Oncology reports 15 (2006) 311-315. 
[94] N. Luplertlop, D. Misse, D. Bray, V. Deleuze, J.P. Gonzalez, V. Leardkamolkarn, H. 
Yssel, F. Veas, Dengue-virus-infected dendritic cells trigger vascular leakage through 
metalloproteinase overproduction, EMBO reports 7 (2006) 1176-1181. 
[95] D. Navaratna, P.G. McGuire, G. Menicucci, A. Das, Proteolytic Degradation of VE-
Cadherin Alters the Blood-Retinal Barrier in Diabetes, Diabetes  (2007). 
[96] W.B. Wu, T.F. Huang, Activation of MMP-2, cleavage of matrix proteins, and 
adherens junctions during a snake venom metalloproteinase-induced endothelial cell 
apoptosis, Exp Cell Res 288 (2003) 143-157. 
[97] K. Xiao, D.F. Allison, K.M. Buckley, M.D. Kottke, P.A. Vincent, V. Faundez, A.P. 
Kowalczyk, Cellular levels of p120 catenin function as a set point for cadherin 
expression levels in microvascular endothelial cells, J Cell Biol 163 (2003) 535-545. 
[98] K. Xiao, D.F. Allison, M.D. Kottke, S. Summers, G.P. Sorescu, V. Faundez, A.P. 
Kowalczyk, Mechanisms of VE-cadherin processing and degradation in microvascular 
endothelial cells, J Biol Chem 278 (2003) 19199-19208. 
[99] S. Iyer, D.M. Ferreri, N.C. DeCocco, F.L. Minnear, P.A. Vincent, VE-cadherin-p120 
interaction is required for maintenance of endothelial barrier function, Am J Physiol 
Lung Cell Mol Physiol 286 (2004) L1143-1153. 
[100] K. Xiao, J. Garner, K.M. Buckley, P.A. Vincent, C.M. Chiasson, E. Dejana, V. 
Faundez, A.P. Kowalczyk, p120-Catenin regulates clathrin-dependent endocytosis of 
VE-cadherin, Mol Biol Cell 16 (2005) 5141-5151. 
[101] L. Caveda, I. Martin-Padura, P. Navarro, F. Breviario, M. Corada, D. Gulino, M.G. 
Lampugnani, E. Dejana, Inhibition of cultured cell growth by vascular endothelial 
cadherin (cadherin-5/VE-cadherin), J Clin Invest 98 (1996) 886-893. 
[102] M. Pierce, C. Wang, M. Stump, A. Kamb, Overexpression of the beta-catenin binding 
domain of cadherin selectively kills colorectal cancer cells, International journal of 
cancer 107 (2003) 229-237. 
[103] M.G. Lampugnani, F. Orsenigo, M.C. Gagliani, C. Tacchetti, E. Dejana, Vascular 
endothelial cadherin controls VEGFR-2 internalization and signaling from 
intracellular compartments, J Cell Biol 174 (2006) 593-604. 
[104] A. Zanetti, M.G. Lampugnani, G. Balconi, F. Breviario, M. Corada, L. Lanfrancone, 
E. Dejana, Vascular endothelial growth factor induces SHC association with vascular 
endothelial cadherin: a potential feedback mechanism to control vascular endothelial 
growth factor receptor-2 signaling, Arterioscler Thromb Vasc Biol 22 (2002) 617-622. 
[105] G. Pelicci, L. Lanfrancone, F. Grignani, J. McGlade, F. Cavallo, G. Forni, I. Nicoletti, 
F. Grignani, T. Pawson, P.G. Pelicci, A novel transforming protein (SHC) with an 
SH2 domain is implicated in mitogenic signal transduction, Cell 70 (1992) 93-104. 
[106] S.C. Harrison, Variation on an Src-like theme, Cell 112 (2003) 737-740. 
[107] L.J. Duan, A. Imamoto, G.H. Fong, Dual roles of the C-terminal Src kinase (Csk) 
during developmental vascularization, Blood 103 (2004) 1370-1372. 
20 
[108] C.M. Nelson, C.S. Chen, VE-cadherin simultaneously stimulates and inhibits cell 
proliferation by altering cytoskeletal structure and tension, J Cell Sci 116 (2003) 3571-
3581. 
[109] R. Spagnuolo, M. Corada, F. Orsenigo, L. Zanetta, U. Deuschle, P. Sandy, C. 
Schneider, C.J. Drake, F. Breviario, E. Dejana, Gas1 is induced by VE-cadherin and 
vascular endothelial growth factor and inhibits endothelial cell apoptosis, Blood 103 
(2004) 3005-3012. 
[110] H.J. Schnittler, B. Puschel, D. Drenckhahn, Role of cadherins and plakoglobin in 
interendothelial adhesion under resting conditions and shear stress, Am J Physiol 273 
(1997) H2396-2405. 
[111] A. Shay-Salit, M. Shushy, E. Wolfovitz, H. Yahav, F. Breviario, E. Dejana, N. 
Resnick, VEGF receptor 2 and the adherens junction as a mechanical transducer in 
vascular endothelial cells, Proc Natl Acad Sci U S A 99 (2002) 9462-9467. 
[112] E. Tzima, M. Irani-Tehrani, W.B. Kiosses, E. Dejana, D.A. Schultz, B. Engelhardt, G. 
Cao, H. DeLisser, M.A. Schwartz, A mechanosensory complex that mediates the 
endothelial cell response to fluid shear stress, Nature 437 (2005) 426-431. 
[113] J. Waschke, W. Baumgartner, R.H. Adamson, M. Zeng, K. Aktories, H. Barth, C. 
Wilde, F.E. Curry, D. Drenckhahn, Requirement of Rac activity for maintenance of 
capillary endothelial barrier properties, American journal of physiology 286 (2004) 
H394-401. 
[114] J. Waschke, D. Drenckhahn, R.H. Adamson, F.E. Curry, Role of adhesion and 
contraction in Rac 1-regulated endothelial barrier function in vivo and in vitro, 
American journal of physiology 287 (2004) H704-711. 
[115] B. Wojciak-Stothard, L.Y. Tsang, S.G. Haworth, Rac and Rho play opposing roles in 
the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary 
artery endothelial cells, Am J Physiol Lung Cell Mol Physiol 288 (2005) L749-760. 
[116] Y. Liu, D.R. Senger, Matrix-specific activation of Src and Rho initiates capillary 
morphogenesis of endothelial cells, Faseb J 18 (2004) 457-468. 
[117] J. Seebach, H.J. Madler, B. Wojciak-Stothard, H.J. Schnittler, Tyrosine 
phosphorylation and the small GTPase rac cross-talk in regulation of endothelial 
barrier function, Thrombosis and haemostasis 94 (2005) 620-629. 
[118] S. van Wetering, J.D. van Buul, S. Quik, F.P. Mul, E.C. Anthony, J.P. ten Klooster, 
J.G. Collard, P.L. Hordijk, Reactive oxygen species mediate Rac-induced loss of cell-
cell adhesion in primary human endothelial cells, J Cell Sci 115 (2002) 1837-1846. 
[119] J.D. van Buul, E.C. Anthony, M. Fernandez-Borja, K. Burridge, P.L. Hordijk, Proline-
rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell 
adhesion by regulating beta-catenin tyrosine phosphorylation, J Biol Chem 280 (2005) 
21129-21136. 
[120] M.G. Lampugnani, A. Zanetti, F. Breviario, G. Balconi, F. Orsenigo, M. Corada, R. 
Spagnuolo, M. Betson, V. Braga, E. Dejana, VE-cadherin regulates endothelial actin 
activating Rac and increasing membrane association of Tiam, Mol Biol Cell 13 (2002) 
1175-1189. 
[121] C.M. Nelson, D.M. Pirone, J.L. Tan, C.S. Chen, Vascular endothelial-cadherin 
regulates cytoskeletal tension, cell spreading, and focal adhesions by stimulating 
RhoA, Mol Biol Cell 15 (2004) 2943-2953. 
[122] P. Kouklis, M. Konstantoulaki, S. Vogel, M. Broman, A.B. Malik, Cdc42 regulates 
the restoration of endothelial barrier function, Circ Res 94 (2004) 159-166. 
[123] M.T. Broman, P. Kouklis, X. Gao, R. Ramchandran, R.F. Neamu, R.D. Minshall, A.B. 
Malik, Cdc42 regulates adherens junction stability and endothelial permeability by 
21 
inducing alpha-catenin interaction with the vascular endothelial cadherin complex, 
Circ Res 98 (2006) 73-80. 
[124] P. Kouklis, M. Konstantoulaki, A.B. Malik, VE-cadherin-induced Cdc42 signaling 
regulates formation of membrane protrusions in endothelial cells, J Biol Chem 278 
(2003) 16230-16236. 
[125] J. Martinez, A. Ferber, T.L. Bach, C.H. Yaen, Interaction of fibrin with VE-cadherin, 
Ann N Y Acad Sci 936 (2001) 386-405. 
[126] T.J. Stelzner, J.V. Weil, R.F. O'Brien, Role of cyclic adenosine monophosphate in the 
induction of endothelial barrier properties, Journal of cellular physiology 139 (1989) 
157-166. 
[127] P.J. Farmer, S.G. Bernier, A. Lepage, G. Guillemette, D. Regoli, P. Sirois, 
Permeability of endothelial monolayers to albumin is increased by bradykinin and 
inhibited by prostaglandins, Am J Physiol Lung Cell Mol Physiol 280 (2001) L732-
738. 
[128] S. Fukuhara, A. Sakurai, H. Sano, A. Yamagishi, S. Somekawa, N. Takakura, Y. 
Saito, K. Kangawa, N. Mochizuki, Cyclic AMP potentiates vascular endothelial 
cadherin-mediated cell-cell contact to enhance endothelial barrier function through an 
Epac-Rap1 signaling pathway, Mol Cell Biol 25 (2005) 136-146. 
[129] M.R. Kooistra, M. Corada, E. Dejana, J.L. Bos, Epac1 regulates integrity of 
endothelial cell junctions through VE-cadherin, FEBS letters 579 (2005) 4966-4972. 
[130] A. Sakurai, S. Fukuhara, A. Yamagishi, K. Sako, Y. Kamioka, M. Masuda, Y. 
Nakaoka, N. Mochizuki, MAGI-1 is required for Rap1 activation upon cell-cell 
contact and for enhancement of vascular endothelial cadherin-mediated cell adhesion, 
Mol Biol Cell 17 (2006) 966-976. 
[131] W.C. Aird, Phenotypic heterogeneity of the endothelium: II. Representative vascular 
beds, Circ Res 100 (2007) 174-190. 
[132] W.C. Aird, Phenotypic heterogeneity of the endothelium: I. Structure, function, and 
mechanisms, Circ Res 100 (2007) 158-173. 
[133] J.H. Kim, J.H. Kim, J.A. Park, S.W. Lee, W.J. Kim, Y.S. Yu, K.W. Kim, Blood-
neural barrier: intercellular communication at glio-vascular interface, Journal of 
biochemistry and molecular biology 39 (2006) 339-345. 
[134] C.H. Lai, K.H. Kuo, The critical component to establish in vitro BBB model: Pericyte, 
Brain research 50 (2005) 258-265. 
[135] M. Furuse, S. Tsukita, Claudins in occluding junctions of humans and flies, Trends in 
cell biology 16 (2006) 181-188. 
[136] S. Hori, S. Ohtsuki, K. Hosoya, E. Nakashima, T. Terasaki, A pericyte-derived 
angiopoietin-1 multimeric complex induces occludin gene expression in brain 
capillary endothelial cells through Tie-2 activation in vitro, Journal of neurochemistry 
89 (2004) 503-513. 
[137] S. Dohgu, F. Takata, A. Yamauchi, S. Nakagawa, T. Egawa, M. Naito, T. Tsuruo, Y. 
Sawada, M. Niwa, Y. Kataoka, Brain pericytes contribute to the induction and up-
regulation of blood-brain barrier functions through transforming growth factor-beta 
production, Brain Res 1038 (2005) 208-215. 
[138] S. Dohgu, A. Yamauchi, F. Takata, M. Naito, T. Tsuruo, S. Higuchi, Y. Sawada, Y. 
Kataoka, Transforming growth factor-beta1 upregulates the tight junction and P-
glycoprotein of brain microvascular endothelial cells, Cellular and molecular 
neurobiology 24 (2004) 491-497. 
[139] S. Aijaz, M.S. Balda, K. Matter, Tight junctions: molecular architecture and function, 
International review of cytology 248 (2006) 261-298. 
22 
[140] K. Morita, H. Sasaki, K. Furuse, M. Furuse, S. Tsukita, Y. Miyachi, Expression of 
claudin-5 in dermal vascular endothelia, Experimental dermatology 12 (2003) 289-
295. 
[141] T. Nitta, M. Hata, S. Gotoh, Y. Seo, H. Sasaki, N. Hashimoto, M. Furuse, S. Tsukita, 
Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice, J Cell 
Biol 161 (2003) 653-660. 
[142] J.C. Challier, G. Dubernard, M. Galtier, T. Bintein, C. Vervelle, D. Raison, M.J. 
Espie, S. Uzan, Junctions and adhesion molecules in first trimester and term human 
placentas, Cellular and molecular biology (Noisy-le-Grand, France) 51 Suppl (2005) 
OL713-722. 
[143] S. Lievano, L. Alarcon, B. Chavez-Munguia, L. Gonzalez-Mariscal, Endothelia of 
term human placentae display diminished expression of tight junction proteins during 
preeclampsia, Cell and tissue research 324 (2006) 433-448. 
[144] H. Wolburg, K. Wolburg-Buchholz, J. Kraus, G. Rascher-Eggstein, S. Liebner, S. 
Hamm, F. Duffner, E.H. Grote, W. Risau, B. Engelhardt, Localization of claudin-3 in 
tight junctions of the blood-brain barrier is selectively lost during experimental 
autoimmune encephalomyelitis and human glioblastoma multiforme, Acta 
neuropathologica 105 (2003) 586-592. 
[145] B.E. Enerson, L.R. Drewes, The rat blood-brain barrier transcriptome, J Cereb Blood 
Flow Metab 26 (2006) 959-973. 
[146] S. Liebner, A. Fischmann, G. Rascher, F. Duffner, E.H. Grote, H. Kalbacher, H. 
Wolburg, Claudin-1 and claudin-5 expression and tight junction morphology are 
altered in blood vessels of human glioblastoma multiforme, Acta neuropathologica 
100 (2000) 323-331. 
[147] G. Bazzoni, Endothelial tight junctions: permeable barriers of the vessel wall, 
Thrombosis and haemostasis 95 (2006) 36-42. 
[148] D.C. Davies, Blood-brain barrier breakdown in septic encephalopathy and brain 
tumours, Journal of anatomy 200 (2002) 639-646. 
[149] N.S. Harhaj, D.A. Antonetti, Regulation of tight junctions and loss of barrier function 
in pathophysiology, Int J Biochem Cell Biol 36 (2004) 1206-1237. 
[150] A. MacIntyre, C.J. Hammond, C.S. Little, D.M. Appelt, B.J. Balin, Chlamydia 
pneumoniae infection alters the junctional complex proteins of human brain 
microvascular endothelial cells, FEMS microbiology letters 217 (2002) 167-172. 
[151] N. Sawada, M. Murata, K. Kikuchi, M. Osanai, H. Tobioka, T. Kojima, H. Chiba, 
Tight junctions and human diseases, Med Electron Microsc 36 (2003) 147-156. 
[152] B.T. Hawkins, T.J. Abbruscato, R.D. Egleton, R.C. Brown, J.D. Huber, C.R. Campos, 
T.P. Davis, Nicotine increases in vivo blood-brain barrier permeability and alters 
cerebral microvascular tight junction protein distribution, Brain Res 1027 (2004) 48-
58. 
[153] D.A. Antonetti, A.J. Barber, S. Khin, E. Lieth, J.M. Tarbell, T.W. Gardner, Vascular 
permeability in experimental diabetes is associated with reduced endothelial occludin 
content: vascular endothelial growth factor decreases occludin in retinal endothelial 
cells. Penn State Retina Research Group, Diabetes 47 (1998) 1953-1959. 
[154] K.K. Erickson, J.M. Sundstrom, D.A. Antonetti, Vascular permeability in ocular 
disease and the role of tight junctions, Angiogenesis 10 (2007) 103-117. 
[155] J.D. Huber, R.D. Egleton, T.P. Davis, Molecular physiology and pathophysiology of 
tight junctions in the blood-brain barrier, Trends in neurosciences 24 (2001) 719-725. 
[156] P. Vajkoczy, M.D. Menger, Vascular microenvironment in gliomas, Journal of neuro-
oncology 50 (2000) 99-108. 
23 
[157] R.C. Brown, T.P. Davis, Calcium modulation of adherens and tight junction function: 
a potential mechanism for blood-brain barrier disruption after stroke, Stroke; a journal 
of cerebral circulation 33 (2002) 1706-1711. 
[158] R.C. Brown, T.P. Davis, Hypoxia/aglycemia alters expression of occludin and actin in 
brain endothelial cells, Biochem Biophys Res Commun 327 (2005) 1114-1123. 
[159] M. Saitou, M. Furuse, H. Sasaki, J.D. Schulzke, M. Fromm, H. Takano, T. Noda, S. 
Tsukita, Complex phenotype of mice lacking occludin, a component of tight junction 
strands, Mol Biol Cell 11 (2000) 4131-4142. 
[160] M.A. Behzadian, L.J. Windsor, N. Ghaly, G. Liou, N.T. Tsai, R.B. Caldwell, VEGF-
induced paracellular permeability in cultured endothelial cells involves urokinase and 
its receptor, Faseb J 17 (2003) 752-754. 
[161] A. Reijerkerk, G. Kooij, S.M. van der Pol, S. Khazen, C.D. Dijkstra, H.E. de Vries, 
Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in 
brain endothelial cells, Faseb J 20 (2006) 2550-2552. 
[162] M. Wachtel, K. Frei, E. Ehler, A. Fontana, K. Winterhalter, S.M. Gloor, Occludin 
proteolysis and increased permeability in endothelial cells through tyrosine 
phosphatase inhibition, J Cell Sci 112 ( Pt 23) (1999) 4347-4356. 
[163] D.A. Antonetti, A.J. Barber, L.A. Hollinger, E.B. Wolpert, T.W. Gardner, Vascular 
endothelial growth factor induces rapid phosphorylation of tight junction proteins 
occludin and zonula occluden 1. A potential mechanism for vascular permeability in 
diabetic retinopathy and tumors, J Biol Chem 274 (1999) 23463-23467. 
[164] N.S. Harhaj, E.A. Felinski, E.B. Wolpert, J.M. Sundstrom, T.W. Gardner, D.A. 
Antonetti, VEGF activation of protein kinase C stimulates occludin phosphorylation 
and contributes to endothelial permeability, Investigative ophthalmology & visual 
science 47 (2006) 5106-5115. 
[165] L. DeMaio, Y.S. Chang, T.W. Gardner, J.M. Tarbell, D.A. Antonetti, Shear stress 
regulates occludin content and phosphorylation, American journal of physiology 281 
(2001) H105-113. 
[166] L. DeMaio, M. Rouhanizadeh, S. Reddy, A. Sevanian, J. Hwang, T.K. Hsiai, Oxidized 
phospholipids mediate occludin expression and phosphorylation in vascular 
endothelial cells, American journal of physiology 290 (2006) H674-683. 
[167] T. Hirase, S. Kawashima, E.Y. Wong, T. Ueyama, Y. Rikitake, S. Tsukita, M. 
Yokoyama, J.M. Staddon, Regulation of tight junction permeability and occludin 
phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms, J 
Biol Chem 276 (2001) 10423-10431. 
[168] S.M. Stamatovic, O.B. Dimitrijevic, R.F. Keep, A.V. Andjelkovic, Protein kinase 
Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial 
permeability, J Biol Chem 281 (2006) 8379-8388. 
[169] K. Wosik, R. Cayrol, A. Dodelet-Devillers, F. Berthelet, M. Bernard, R. Moumdjian, 
A. Bouthillier, T.L. Reudelhuber, A. Prat, Angiotensin II controls occludin function 
and is required for blood brain barrier maintenance: relevance to multiple sclerosis, J 
Neurosci 27 (2007) 9032-9042. 
[170] T. Kago, N. Takagi, I. Date, Y. Takenaga, K. Takagi, S. Takeo, Cerebral ischemia 
enhances tyrosine phosphorylation of occludin in brain capillaries, Biochem Biophys 
Res Commun 339 (2006) 1197-1203. 
[171] D.A. Antonetti, E.B. Wolpert, L. DeMaio, N.S. Harhaj, R.C. Scaduto, Jr., 
Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with 
increased content and decreased phosphorylation of occludin, Journal of 
neurochemistry 80 (2002) 667-677. 
24 
[172] M.S. Balda, J.M. Anderson, Two classes of tight junctions are revealed by ZO-1 
isoforms, Am J Physiol 264 (1993) C918-924. 
[173] E. Willott, M.S. Balda, M. Heintzelman, B. Jameson, J.M. Anderson, Localization and 
differential expression of two isoforms of the tight junction protein ZO-1, Am J 
Physiol 262 (1992) C1119-1124. 
[174] H. Kurihara, J.M. Anderson, M.G. Farquhar, Diversity among tight junctions in rat 
kidney: glomerular slit diaphragms and endothelial junctions express only one isoform 
of the tight junction protein ZO-1, Proc Natl Acad Sci U S A 89 (1992) 7075-7079. 
[175] B.H. Keon, S. Schafer, C. Kuhn, C. Grund, W.W. Franke, Symplekin, a novel type of 
tight junction plaque protein, J Cell Biol 134 (1996) 1003-1018. 
[176] M. Aurrand-Lions, C. Johnson-Leger, C. Wong, L. Du Pasquier, B.A. Imhof, 
Heterogeneity of endothelial junctions is reflected by differential expression and 
specific subcellular localization of the three JAM family members, Blood 98 (2001) 
3699-3707. 
[177] L.A. Williams, I. Martin-Padura, E. Dejana, N. Hogg, D.L. Simmons, Identification 
and characterisation of human Junctional Adhesion Molecule (JAM), Molecular 
immunology 36 (1999) 1175-1188. 
[178] C. Ody, S. Jungblut-Ruault, D. Cossali, M. Barnet, M. Aurrand-Lions, B.A. Imhof, T. 
Matthes, Junctional adhesion molecule C (JAM-C) distinguishes CD27+ germinal 
center B lymphocytes from non-germinal center cells and constitutes a new diagnostic 
tool for B-cell malignancies, Leukemia 21 (2007) 1285-1293. 
[179] A.P. Morris, A. Tawil, Z. Berkova, L. Wible, C.W. Smith, S.A. Cunningham, 
Junctional Adhesion Molecules (JAMs) are differentially expressed in fibroblasts and 
co-localize with ZO-1 to adherens-like junctions, Cell communication & adhesion 13 
(2006) 233-247. 
[180] D. Palmeri, A. van Zante, C.C. Huang, S. Hemmerich, S.D. Rosen, Vascular 
endothelial junction-associated molecule, a novel member of the immunoglobulin 
superfamily, is localized to intercellular boundaries of endothelial cells, J Biol Chem 
275 (2000) 19139-19145. 
[181] T.W. Liang, R.A. DeMarco, R.J. Mrsny, A. Gurney, A. Gray, J. Hooley, H.L. Aaron, 
A. Huang, T. Klassen, D.B. Tumas, S. Fong, Characterization of huJAM: evidence for 
involvement in cell-cell contact and tight junction regulation, Am J Physiol Cell 
Physiol 279 (2000) C1733-1743. 
[182] Y. Liu, A. Nusrat, F.J. Schnell, T.A. Reaves, S. Walsh, M. Pochet, C.A. Parkos, 
Human junction adhesion molecule regulates tight junction resealing in epithelia, J 
Cell Sci 113 ( Pt 13) (2000) 2363-2374. 
[183] E. Dejana, R. Spagnuolo, G. Bazzoni, Interendothelial junctions and their role in the 
control of angiogenesis, vascular permeability and leukocyte transmigration, 
Thrombosis and haemostasis 86 (2001) 308-315. 
[184] H. Ozaki, K. Ishii, H. Horiuchi, H. Arai, T. Kawamoto, K. Okawa, A. Iwamatsu, T. 
Kita, Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes 
redistribution of junctional adhesion molecule in human endothelial cells, J Immunol 
163 (1999) 553-557. 
[185] S. Nourshargh, F. Krombach, E. Dejana, The role of JAM-A and PECAM-1 in 
modulating leukocyte infiltration in inflamed and ischemic tissues, Journal of 
leukocyte biology 80 (2006) 714-718. 
[186] G. Ostermann, K.S. Weber, A. Zernecke, A. Schroder, C. Weber, JAM-1 is a ligand of 
the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes, 
Nature immunology 3 (2002) 151-158. 
25 
[187] M.R. Cera, A. Del Prete, A. Vecchi, M. Corada, I. Martin-Padura, T. Motoike, P. 
Tonetti, G. Bazzoni, W. Vermi, F. Gentili, S. Bernasconi, T.N. Sato, A. Mantovani, E. 
Dejana, Increased DC trafficking to lymph nodes and contact hypersensitivity in 
junctional adhesion molecule-A-deficient mice, J Clin Invest 114 (2004) 729-738. 
[188] V.G. Cooke, M.U. Naik, U.P. Naik, Fibroblast growth factor-2 failed to induce 
angiogenesis in junctional adhesion molecule-A-deficient mice, Arterioscler Thromb 
Vasc Biol 26 (2006) 2005-2011. 
[189] M. Corada, S. Chimenti, M.R. Cera, M. Vinci, M. Salio, F. Fiordaliso, N. De Angelis, 
A. Villa, M. Bossi, L.I. Staszewsky, A. Vecchi, D. Parazzoli, T. Motoike, R. Latini, E. 
Dejana, Junctional adhesion molecule-A-deficient polymorphonuclear cells show 
reduced diapedesis in peritonitis and heart ischemia-reperfusion injury, Proc Natl 
Acad Sci U S A 102 (2005) 10634-10639. 
[190] A. Khandoga, J.S. Kessler, H. Meissner, M. Hanschen, M. Corada, T. Motoike, G. 
Enders, E. Dejana, F. Krombach, Junctional adhesion molecule-A deficiency increases 
hepatic ischemia-reperfusion injury despite reduction of neutrophil transendothelial 
migration, Blood 106 (2005) 725-733. 
[191] M. Aurrand-Lions, L. Duncan, C. Ballestrem, B.A. Imhof, JAM-2, a novel 
immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells, 
J Biol Chem 276 (2001) 2733-2741. 
[192] C. Lamagna, P. Meda, G. Mandicourt, J. Brown, R.J. Gilbert, E.Y. Jones, F. Kiefer, P. 
Ruga, B.A. Imhof, M. Aurrand-Lions, Dual interaction of JAM-C with JAM-B and 
alpha(M)beta2 integrin: function in junctional complexes and leukocyte adhesion, Mol 
Biol Cell 16 (2005) 4992-5003. 
[193] V.V. Orlova, M. Economopoulou, F. Lupu, S. Santoso, T. Chavakis, Junctional 
adhesion molecule-C regulates vascular endothelial permeability by modulating VE-
cadherin-mediated cell-cell contacts, The Journal of experimental medicine 203 
(2006) 2703-2714. 
[194] M. Sircar, P.F. Bradfield, M. Aurrand-Lions, R.J. Fish, P. Alcaide, L. Yang, G. 
Newton, D. Lamont, S. Sehrawat, T. Mayadas, T.W. Liang, C.A. Parkos, B.A. Imhof, 
F.W. Luscinskas, Neutrophil Transmigration under Shear Flow Conditions In Vitro Is 
Junctional Adhesion Molecule-C Independent, J Immunol 178 (2007) 5879-5887. 
[195] C. Fuse, Y. Ishida, T. Hikita, T. Asai, N. Oku, Junctional adhesion molecule-C 
promotes metastatic potential of HT1080 human fibrosarcoma, J Biol Chem 282 
(2007) 8276-8283. 
[196] S. Santoso, V.V. Orlova, K. Song, U.J. Sachs, C.L. Andrei-Selmer, T. Chavakis, The 
homophilic binding of junctional adhesion molecule-C mediates tumor cell-
endothelial cell interactions, J Biol Chem 280 (2005) 36326-36333. 
[197] G. Mandicourt, S. Iden, K. Ebnet, M. Aurrand-Lions, B.A. Imhof, JAM-C regulates 
tight junctions and integrin-mediated cell adhesion and migration, J Biol Chem 282 
(2007) 1830-1837. 
[198] B. Imhof, C. Zimmerli, G. Gliki, D. Ducrest-Gay, P. Juillard, P. Hammel, R. Adams, 
M. Aurrand-Lions, Pulmonary dysfunction and impaired granulocyte homeostasis 
result in poor survival of Jam-C-deficient mice, The Journal of pathology 212 (2007) 
198-208. 
[199] F. Wegmann, K. Ebnet, L. Du Pasquier, D. Vestweber, S. Butz, Endothelial adhesion 
molecule ESAM binds directly to the multidomain adaptor MAGI-1 and recruits it to 
cell contacts, Exp Cell Res 300 (2004) 121-133. 
[200] T. Ishida, R.K. Kundu, E. Yang, K. Hirata, Y.D. Ho, T. Quertermous, Targeted 
disruption of endothelial cell-selective adhesion molecule inhibits angiogenic 
processes in vitro and in vivo, J Biol Chem 278 (2003) 34598-34604. 
26 
[201] F. Wegmann, B. Petri, A.G. Khandoga, C. Moser, A. Khandoga, S. Volkery, H. Li, I. 
Nasdala, O. Brandau, R. Fassler, S. Butz, F. Krombach, D. Vestweber, ESAM 
supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular 
permeability, The Journal of experimental medicine 203 (2006) 1671-1677. 
[202] K. Irie, K. Shimizu, T. Sakisaka, W. Ikeda, Y. Takai, Roles and modes of action of 
nectins in cell-cell adhesion, Seminars in cell & developmental biology 15 (2004) 
643-656. 
[203] H. Nakanishi, Y. Takai, Roles of nectins in cell adhesion, migration and polarization, 
Biol Chem 385 (2004) 885-892. 
[204] M. Lopez, M. Aoubala, F. Jordier, D. Isnardon, S. Gomez, P. Dubreuil, The human 
poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic 




Fig. 1: Electron micrograph showing an endothelial junction in mouse aorta 
The intercellular cleft (between arrowheads) is lined by two endothelial (E) strands and 
extands from basal lamina to lumen (L).  
 
Fig. 2: Adhesive proteins within the interendothelial cleft 
Claudins, occluding, JAMs and ESAM are located in TJs, VE-cadherin in Ajs and connexins 
in gap junctions. Nectin was detected in both Ajs and TJs, while PECAM, Pcdh12, CD99 and 
S-endo-1 are outside of these structures. TJs and Ajs are both linked to the actin cytoskeleton 
and VE-cadherin may also be associated with vimentin filaments in some vascular beds.  
 
Fig. 3: Model of hexameric assembly of VE-cadherin extracellular domains deduced 
from biochemical analyses and electron-microscopy 
Model includes VE-cadherin ectodomains (EC) 1-4. Left: model with the VE-cadherin dimers 
represented in violet, light-green and light-blue. Right: The fit of the VE-cadherin model in 
the reconstructed hexamer. EC1 (red), EC2 (green), EC3 (cyan) and EC4 (blue) are coloured 
as indicated. Reproduced from [27] 
 
Fig. 4: Adherens junctions and complexus adherentes in endothelial cells 
In AJs, VE-cadherin directly interacts at a membrane-distal site with - and ß-catenins and at 
a juxtramembrane site with p120 and p0071. The exact molecular link between the VE-
cadherin-catenin complex and the actin filaments is still obscure. The nectins are linked to the 
actin cytoskeleton via afadin. In complexus adherens, VE-cadherin associates with vimentin 
filaments via plakoglobin/desmoplakin or p0071.  
 
Fig. 5: VEGF-induced VE-cadherin phosphorylation and internalization via Src kinase  
A. VEGF activation induces VEGFR2 dimerization, enabling Src activation, which in turn 
phosphorylates VE-cadherin on Tyr-685 [71, 73]. Csk may associate with VE-cadherin 
phospho-tyr-685. This interaction was shown to inhibit proliferation in high density cell 
cultures [74]. Csk-VE-cadherin interaction may potentially inhibit VE-cadherin-associated 
Src by phophorylating an inhibitory tyrosine in Src C-terminus domain. 
B. Independently,VEGF was shown to induce an activation cascade (Src  Vav2  Rac  
PAK kinase) leading to phosphorylation of VE-cadherin cytoplasmic domain on serine 665. 
Phospho-S665 VE-cadherin becomes a docking site for ß-arrestin-2, the binding of which 
triggers VE-cadherin endocytosis and degradation, and thus, junction opening [76]. More 
work is necessary to examine the interplay between both pathways. 
 
Fig. 6: Participation of VE-cadherin to VEGF signaling 
It is clearly established that VE-cadherin has a pivotal role in contact inhibition of cell 
proliferation. VE-cadherin, through its interaction with Dep-1 or other tyrosine phosphatases 
inhibits VEGF proliferation signal via MAPK activation in three ways: (i) by reducing 
VEGFR2 phosphorylation, (ii) by inhibiting VEGFR2-associated Shc phosphorylation and 
(iii) by decreasing VEGFR2 internalization and signaling from endosomal compartments. 
VE-cadherin complex interaction with activated VEGFR2 also enhances VEGF survival 
signaling by PI3kinase/Akt pathway. 
 
Fig. 7: Rap1 activation pathways and stabilization of the endothelial barrier 
Increased levels of intracellular cAMP by G-protein-coupled receptors enable the activation 
of the exchange factor Epac, which is a specific activator of Rap1, a Ras family GTPase. 
28 
Rap1 activation promotes AJ extension by increasing the avidity of cortical actin to the VE-
cadherin complex. Rap1 may also be activated by the adaptator protein MAGI-I together with 
the exchange factor PDZ-GEF1, recruited at the VE-cadherin complex. These data are derived 
from [128-130]. 
 
Fig. 8: Cytokines activating signaling pathways leading to occludin functional 
alterations (phosphorylation or proteolysis) 
VEGF, MCP-1, lysophosphatidic acid (LPA) and histamine (Hist), by interaction with their 
cognate receptors, VEGFR2, CCR2, LPAR and HistR, respectively, induce increased 
occludin phosphorylation on serine/threonine residues, in correlation with increased 
permeability. Signaling pathways involve PKC activity, PKC and/or RhoA, as indicated 
[163, 164, 167, 168]. VEGF also increases permeability by inducing occludin proteolysis 
through activation of the urokinase (uPA)/uPAR system [153, 160]. Conversely, angiotensin-
2 (AT2) binding to type 1 angiotensin receptor (ATR) decreases permeability by inducing 
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